Aeterna Zentaris Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AEZS.TO research report →
Companywww.zentaris.com
Aeterna Zentaris Inc. , a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications.
- CEO
- Gilles R. Gagnon
- IPO
- 1996
- Employees
- 12
- HQ
- Summerville, SC, US
Price Chart
Valuation
- Market Cap
- $25.38M
- P/E
- -0.78
- P/S
- 0.73
- P/B
- 0.37
- EV/EBITDA
- -0.43
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 37.98%
- Op Margin
- -99.15%
- Net Margin
- -92.11%
- ROE
- -92.59%
- ROIC
- -44.94%
Growth & Income
- Revenue
- $4.50M · -20.25%
- Net Income
- $-3,550,349 · -209.56%
- EPS
- $-1.92 · -202.67%
- Op Income
- $-18,008,000
- FCF YoY
- -25.17%
Performance & Tape
- 52W High
- $12.50
- 52W Low
- $0.19
- 50D MA
- $7.81
- 200D MA
- $7.33
- Beta
- 2.26
- Avg Volume
- 1.79K
Get TickerSpark's AI analysis on AEZS.TO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our AEZS.TO Coverage
We haven't published any research on AEZS.TO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate AEZS.TO Report →